Diminishing the immunogenicity of therapeutic proteins without hindering their function will improve clinical outcomes. This can be accomplished by substitution of key amino acids in the T cell epitope sequences which abrogate binding to HLA and thereby attenuate epitope potential to trigger a T cell response. Altered T cell epitopes no longer bind to HLA. Epitope modifications are easily evaluated in vitro and in vivo prior to release of the protein therapeutic for clinical development. Also, EpiVax has proprietary technology to identify and introduce Tregitopes (T regulatory epitopes) to reduce immunogenicity and induce tolerance (patented technology/approach). This method of reducing immunogenicity, also known as de-immunization (DeFT), is described in further detail here.
- $5.2 Million Department of Defense Grant to “Vaccine on Demand” Consortium
- 4th Computational Vaccinology Workshop at ISV
- About Us
- Business Development Representative
- EpiVax to Advance Development of Vaccine Against Stealth Flu Virus with New NIH-SBIR Funding
- Immune Engineering
- Immunogenicity Screening
- Lab-Based Services Overview
- Sample Page
- Vaccine Design & Redesign
Business InquiriesEpiVax, Inc.
146 Clifford St.
Providence, RI 02903